International medical journal -> Archive -> №1' 2020

№1' 2020

International Medical Journal, Vol. 26., Iss. 1, 2020, P. 33−38.

DOI (https://doi.org/10.37436/2308-5274-2020-1-7)

IMMUNE CHECKPOINT BLOCKADE IN BREAST CANCER THERAPY

Hromakova I. A., Sorochan P. P., Prokhach N. E., Ponamarov I. N., Hromakova I. S., Polozova M. V.

SO "Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine

Despite advances in early detection and treatment, breast cancer remains the deadliest oncopathology for women worldwide. Today there is an urgent need for new approaches to this disease treatment. Recently, immune therapy, especially inhibitors of immune checkpoints, has taken the lead when fighting against cancer. Blocking immune checkpoints is an effective approach to enhance the effector T cell function. Immune checkpoint blockers, namely inhibitors of cytotoxic T−lymphocyte−associated antigen 4 (CTLA−4), programmed cell death protein 1 (PD−1) and ligand 1 of programmed cell death protein 1 (PD−L1) are approved by the US Food and Drug Association (FDA) to be used in various solid tumors, refractory cancers with microsatellite instability, classical Hodgkin's lymphoma. In March 2019, the first inhibitor for the treatment of breast cancer was approved, i.e. atezolizumab (anti−PD−L1) in combination with nab−paclitaxel in the patients with metastatic triple−negative breast cancer, which aroused the interest of experts in the study of immunotherapeutic agents for the treatment of these patients. The review presents the results of using the inhibitors of immune control points in monotherapy and in combination with standard methods of antitumor treatment (chemotherapy and radiotherapy, targeted therapy) in patients with breast cancer. Information on potential biomarkers of response to immunotherapy in breast cancer is presented.

Key words: breast cancer, checkpoint inhibitors, biomarkers of response.

REFERENCES

1. The evaluation of tumor−infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 / R. Salgado et al. // Ann. Oncol. 2015. Vol. 26, № 2. R. 259−271.

2. Clinical relevance of host immunity in breast cancer: from TILs to the clinic / P. Savas et al. // Nat. Rev. Clin. Oncol. 2016. Vol. 13, № 4. R. 228−241. doi: https://doi.org/10.1038/nrclinonc.2015.215

3. Tumour−infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy / C. Denkert et al. // Lancet Oncol. 2018. Vol. 19, № 1. R. 40−50.

4. Tumor−Infiltrating Lymphocytes and Associations with Pathological Complete Response and Event−Free Survival in HER2−Positive Early−Stage Breast Cancer Treated with Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial / R. Salgado et al. // JAMA Oncol. 2015. Vol. 1, № 4. P. 448−454. doi: https://doi.org/10.1001/jamaoncol.2015.0830

5. Association between CD8+ T−cell infiltration and breast cancer survival in 12,439 patients / H. R. Ali et al. // Ann. Oncol. 2014. Vol. 25, № 8. R. 1536−1543.

6. Quantification of regulatory T−cells enables the identification of high−risk breast cancer patients and those at risk of late relapse / G. J. Bates et al. // J. Clin. Oncol. 2006. Vol. 24, № 34. 5373−5380. doi: https://doi.org/10.1200/jco.2006.05.9584

7. Prognostic significance of FOXP3+ tumor−infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor−2 expression status and concurrent cytotoxic T−cell infiltration / S. Liu et al. // Breast Cancer Res. 2014. Vol. 16, № 5. 432 r. doi: https://doi.org/10.1186/s13058−014−0432−8

8. Pembrolizumab in Patients with Advanced Triple−Negative Breast Cancer: Phase Ib KEYNOTE−012 Study / R. Nanda et al. // J. Clin. Oncol. 2016. Vol. 34, № 21. P. 2460−2467. doi: https://doi.org/10.1200/jco.2015.64.8931

9. Pembrolizumab monotherapy for previously treated metastatic triple−negative breast cancer: cohort A of the phase II KEYNOTE−086 study / S. Adams et al. // Ann. Oncol. 2019. Vol. 30, № 3. R. 397−404. doi: https://doi.org/10.1093/annonc/mdy517

10. Pembrolizumab monotherapy for previously untreated, PD−L1−positive, metastatic triple−negative breast cancer: cohort B of the phase II KEYNOTE−086 study / S. Adams et al. // Ann. Oncol. 2019. Vol. 30, № 3. R. 405−411. doi: https://doi.org/10.1093/annonc/mdy518

11. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor−Positive / Human Epidermal Growth Factor Receptor 2−Negative Advanced Breast Cancer / H. S. Rugo et al. // Clin. Cancer Res. 2018. Vol. 24, № 12. R. 2804−2811. doi: https://doi.org/10.1158/1078−0432.ccr−17−3452

12. Long−term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple−Negative Breast Cancer: A Phase 1 Study / L. A. Emens et al. // JAMA Oncol. 2019. Vol. 5, № 1. R. 74−82. doi: https://doi.org/10.3410/f.734027977.793562867

13. Avelumab, an anti−PD−L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study / L.Y. Dirix et al. // Breast Cancer Res. Treat. 2018. Vol. 167, № 3. P. 671−686. doi: https://doi.org/10.3410/f.732029486.793559071

14. Tolaney S. M., Kalinsky K., Kaklamani V. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple−negative breast cancer // Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5 − 9; San Antonio // Cancer Res. 2018. Vol. 78, № 4 (Suppl.). Abstract PD6−13. doi: https://doi.org/10.1158/1538−7445.sabcs17−pd6−13

15. Atezolizumab Plus nab−Paclitaxel in the Treatment of Metastatic Triple−Negative Breast Cancer with 2−Year Survival Follow−up: A Phase 1b Clinical Trial / S. Adams et al. // JAMA Oncol. 2019. Vol. 5, № 3. R. 334−342. doi: https://doi.org/10.1001/jamaoncol.2018.5152

16. Atezolizumab and Nab−Paclitaxel in Advanced Triple−Negative Breast Cancer / P. Schmid et al. // N. Engl. J. Med. 2018. Vol. 379, № 22. P. 2108−2121.

17. Pembrolizumab plus standard neoadjuvant therapy for high−risk breast cancer (BC): results from I−SPY 2 / R. Nanda et al. // J. Clin. Oncol. 2017. URL: https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.506

18. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane−based neoadjuvant therapy in early triple−negative breast cancer: clinical results and biomarker analysis of GeparNuevo study / S. Loibl et al. // Ann. Oncol. 2019. Vol. 30, № 8. R. 1279−1288. doi: https://doi.org/10.1093/annonc/mdz158

19. Hu Z. I., Ho A. Y., McArthur H. L. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer // Int. J. Radiat. Oncol. Biol. Phys. 2017. Vol. 99, № 1. P. 153−164. doi: https://doi.org/10.1016/j.ijrobp.2017.05.029

20. A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC) / H. L. McArthur et al. // J. Clin. Oncol. 2018. Vol. 36 (suppl.). abstr. 1017. doi: https://doi.org/10.1200/jco.2018.36.15_suppl.1017

21. A Pilot Study of Preoperative Single−Dose Ipilimumab and/or Cryoablation in Women with Early−Stage Breast Cancer with Comprehensive Immune Profiling / H. L. McArthur et al / Clin. Cancer Res. 2016. Vol. 22, № 23. P. 5729−5737. doi: https://doi.org/10.1158/1078−0432.ccr−16−0190

22. Pembrolizumab plus trastuzumab in trastuzumab−resistant, advanced, HER2−positive breast cancer (PANACEA): a single−arm, multicentre, phase 1b−2 trial / S. Loi et al. // Lancet Oncol. 2019. Vol. 20, № 3. P. 371−382.

23. Abstract P1−09−01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor−positive (HR+), human epidermal growth factor receptor 2−negative (HER2−) metastatic breast cancer (MBC) / H. S. Rugo et al. // Cancer Res. 2018. Vol. 78, (4 Suppl.). abstract P1−09−01. doi: https://doi.org/10.1158/1538−7445.sabcs17−p1−09−01

24. Rugo H. S., Delord J. P., Im S. A. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor−Positive / Human Epidermal Growth Factor Receptor 2−Negative Advanced Breast Cancer // Clin. Cancer. Res. 2018. Vol. 24, № 12. R. 2804−2811. doi: https://doi.org/10.1158/1078−0432.ccr−17−3452

25. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer / M. N. Dickler et al. // Clin. Cancer. Res. 2017. Vol. 23, № 17. P. 5218−5224. doi: https://doi.org/10.1158/1078−0432.ccr−17−0754

26. An open−label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA−mutated (g BRCA m) HER2−negative metastatic breast cancer (MBC) / S. Domchek et al. // Cancer Res. 2018. Vol. 78, (4 Suppl). abstract PD6−11. doi: https://doi.org/10.3410/f.735553930.793559067

27. Vinayak S., Tolaney S. M., Schwartzberg L. S. TOPACIO/Keynote−162: Niraparib + pembrolizumab in patients (pts) with metastatic triple−negative breast cancer (TNBC), a phase 2 trial // JCO. 2018. Vol. 36. 1011 p. doi: https://doi.org/10.3410/f.734567058.793559068

28. Prognostic value of tumor−infiltrating lymphocytes in triple−negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 / S. Adams et al. // J. Clin. Oncol. 2014. Vol. 32, № 27. P. 2959−2966. doi: https://doi.org/10.1200/jco.2013.55.0491

29. Prognostic and predictive value of tumor infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node−positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin−based chemotherapy: BIG 02−98 / S. Loi et al. // J. Clin. Oncol. 2013. Vol. 31, № 7. P. 860−867. doi: https://doi.org/10.3410/f.717976513.793471389

30. Schmid P., Cruz C., Braiteh F. S. Atezolizumab in metastatic TNBC (mTNBC): Long−term clinical outcomes and biomarker analyses // AACR Annual Meeting, april 1−5, 2017, Washington, DC. Abstract 2986. doi: https://doi.org/10.1158/1538−7445.am2017−2986

ARCHIVE

№1' 2020